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Summary
Amounts of human brain thromboplastin that do not stimulate
thrombin generation in platelet poor plasma, were shown to
advance by about 4 min an explosive formation of thrombin that
occurs after recalcification in the presence of blood platelets. This
synergistic effect is inhibited by the specific thrombin inhibitor
hirudin and mimicked by adding low concentrations (< 5 nM) of
thrombin to platelet r ich phsma. I t  is our conclusion that small
amounts of thrombin, generated under the inf luence of thrombo-
plastin induced procoagulant act ivi ty in the blood platelets. This
activi tv is most l ikely mainly due to procoagulant phospholipids.
Heparin inhibits this effect and retards the explosive thrombin
formation. I t  does not, however, diminish the peak amount of
thrombin eventual lv formed. because heparin neutral izing mate-
r ial released irom the activated platelets quenches the heparin
e ffect -
lntroduction
Thrombin formation and blood platelet reactions are int i-
mately l inked in haemostasis and thrombosis. Thrombin is the
most potent biological platelet act ivator and activated platelets
have important procoagulant properties. The concentration of
thrombin necessary to trigger a half maximal platelet reaction is
signif icantly lower than that of other physiological act ivators
(ADB thromboxane A", PAF-acether) (1,2). The membrane of
the intact platelets can undergo a transbi layer rearrangement of
i ts phospholipids that makes procoagulant phospholipids (mainly
phosphalidyl serine) available at the surface of the intact cell. In
rvashed platelets at a concenrrat ion of 106 platelets/ml, thrombin
plus collagen is the specific trigger for this process (2,3).
Activated platelets release a variety of substances, including
coagulation factor V and platelet factor 4 (PF 4), a protein that
neutral izes heparin (4-8). I t  also has'been reported that ADP
activated platelets trigger coagulation via a factor XII dependent
pathway and that collagen activated platelets cause coagulation in
a factor XI dependent pathway that bypasses factor XII (9, 10).
From these phenomena, observed mostly with isolated
platelets, it is clear that in vivo there must exist several forms of
close cooperation between the blood coagulation system and
platelets. In vivo; haemostasis will usually be started by the
release of tissue factor from wounded cells. Tissue factor is a
lipoprotein,. present in. most mammalian cells, but not in blood
platelets. It activates factor WI and thus starts the reaction
sequence that leads to thrombin formation (11). In order to
investigate the interplay between tissue factor, blood platelets and
the plasmatic coagulation factors under in vitro conditions that
approach the in vivo situation, we have compared the influence ot
human brain thromboplastin on thrombin generation in platelet
rich and platelet poor plasma,
We found that concentrations of thromboplastin that are
without effect oo platelet poor plasma, significantly advance the
generation of thrombin in platelet rich plasma. Untractionated
heparin inhibited the onset of thrombin generation but not the
thrombin yield.
Materials and Methods
Buf i 'e rs :  A :0 .05  M Tr is ,0 .  I M NaCl .  pH 7 .35 .  B :0  6  M ' I i i s ,0  1  M
NaCI ,20  mM EDTA,0 .5  mg/ml  ova lbumin ,  pH7.9 .
Calcium chloride 0.1 M adjusted to pH 7.35.
Chromogenic substrate. 5?238 (Hd-Phe-Pip-Arg-p-nitroani l ide) was
supplied by AB Kabi Diagnostica (Stockholm).
Human brain thromboplastin was uscd as a sourcc of tissue factor. It
was prepared according to Owren and Aas (12), homogenized in a.Potter
Elvehjem homogeniser for 3 min, centrifugated at 2,Ofi) g for i5 min and
stored at -20'C in 0.1ml al iauots. Beibre use i t  was thawcd. di luted with
0.1 M calcium chloridc adjustcd to pH 7.35 and prcincubated I hr at 37'C.
Hirudin was obtained from Sigma (St. Louis, USA).
Platelet rich plasma was obtained by centrifugation (200 x g, 15 min) of
freshly drawn citrated blood from a fasting donor; I volume trisodium
citrate 0. 13 M to 9 volumes blood. The olatelet count was adiusted to
3 x 108/ml with homologous platelet poor plasma (ccntrifuged for l5 min
at 10,000 x g). Plastic tubes and pipettes were used throughout so as to
mrnlmrze contact actrvahon.
Tlvombin Generation
The reaction mixture consisted of 240 pl plasma and 60 pl of buffer A
with or without heparin. The samples were kept at3'7"C and magnetically
stirred. Thrombin formation was started by addition of 60 pl of CaCI2
(0.1 M) in which thromboplastin was diluted to the desired concentration.
In order to obtain comparable results independent of platelet aging,
two to four experiments were run in parallel. At i0 sec intervals al0pl
sample was taken from each of the mixtures and tested for thrombin. In
this way the sampling interval for each mixture is 20-40 sec. A
computerised registration of sampling times was used (13). The plasma
could not be previously defibrinated as this would cause loss of the
platelets. A plastic rod was placed in the samples and as soon as the clot
was formed it was wound on the rod and removed. This did not interfere
with the 10 sec sampling rhythm. The 10 pl samples were transferred to
490 pl of buffer B contaioing 0.2 mM 52238. After about 2 min the
reaction was stopped with 300pI of concentrated acetic acid. The time of
stopping the reaction was again recorded by the, computer- Optical
densities (O.D.) were measured in an LKB Ultrospec II spectrophoto-
meter at 405 nm. From the optical density the recorded incubation inter-
val and the proportionality factor (1 O.D. unit/min = 725 nmol thrombin/l)
the comDuter calculated the thrombin content of the samples.
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Fig. ) Thc influence of thromboplastin on thrombin gencration in
plate let  r ich plasma (PRP) and in p late let  poor p lasma (PPP) Thrombin
generat ion in PRP (sol id l inc)  and PPP (broken l ine) at  a f inal  d i lut ion
(r ' iv)  of  1n40 Q) or  1/2-400 (A) and Car* (25 mM) or  25 mM Ca2+ alone
(I)  Expcr imental  condi t rons as descr ibed in Mater ia ls and Methods
Results
First we determined what di lut ion of thromboplastin would. in
platelet poor plasma. cause less then 10 nM of thrombin to be
formed in the course of 20 min With our thromboplastin
prcparation this turned out to be a 1:2,000 f inal di lut ion We
dcc ided to  usc  a  somewhat  lowcr  amount  (1 :2 .400)  in  our
cxperimenrs in platelct r ich plasma
ln  p la te le t  r i ch  p lasma wi thout  th rombop iasr in .  a  burs r  o f
th rombin  fo rmat ion  is  secn a f tc r  a  Iag  t imc o f  about  9  min  Th is
lag t ime is shortened to 4 min in the presencc of 1:2,400 di luted
thrombop las t in .  A t  h igher  th romhop las t in  concent ra t ions  (1 :240)
thc dif ference between piatelet r ich- and poor plasma vanishes
( F i g .  1 ) .
The shortening of the lag t ime is dependent upon thromboplas-
t in-factor VII interaction because i t  is not seen in congenital
factor VII deficient platelet r ich plasma (Fig.2) Thrombin
generation in the absence of thromboplastin must be mainl l
caused b1, contact activation because it is much retarded in
platelet r ich plasma from a congenital factor XII deficient patient
( F i g . 3 ) .
These results suggest that a common product of extrinsic and
intr insic coagulat ion is responsible for the thrombin burst in
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Fig 2 Thrombin generation in mngenital factor VII deficient platelct
r ich plasma Symbols used. (O). 1/240 di luted thromboplastin: (t ' ) .
1/2.400 di luted thromboplastin and ( l) .  no thromboplastin Sec Matcrials
and Methods for experimental detai ls
plarelet r ich plasma lf  hirudin, a specif ic inhibitor of thrombin is
added to the mixture, the lag phase in the presence of thrombo-
plastin is prolonged in a dose dependent way (Fig.4). As 1 U/ml
of hirudin neutral izes 8- 10 nM of thrombin. the shortening of thc
lag t ime seems 10 be caused b1, lou, concentrat ions of thrombin
produced under the inf luence of thromboplastin I f  thromboplas-
t in is replaced bv nanomolar amounts of thrombin. the lag phasc
is shortened dose dependentlr '  (Fig 4) When the same experi-
ments were performed with platelet poor plasma. preincubarion
rvith thrombin had no effect on thc thrombin gencration curvc.
These f indings suggest that low concentrat ions of thrombin. eithcr
generated during the init ial  stage of thc coagulat ion process or
added io plasma, activate platelets. As a result platelet procoagu-
lant act ivi tv is generated and causes an explosive thrombin
generatron
We tr ied to determine the nature of the platelet procoagulant
activit.v that might be responsible for the effect observed. There
are two obvious candidates, platelet factor V and procoagulant
phospholipids. We mimicked the effect of either of the two b1,
adding 10 nM factor Vu or 40 pM phospholipid (20% phos-
phatidylserine and 80% phosphatidylcholine) to the platelet rich
plasma. These amounts of procoagulant phospholipid and factor
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Fig 3 Thrombin generation in congenital factor XII deficient platelet
r ich plasma. Symbols used:  (O),  1/2.400 di luted thromboplast in;  ( I ) .  no
thromboplastin and (A), no thromboplastin in platelet poor plasma. Sec
Materials und Methods for exoerimental details
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Fig 1 The effect of hirudin and thrombin on the lag time of thrombin
generation in platelet rich plasma The thromboplastin dilution was
1/2.400 and experimental conditions as in Fig. 1
Hirudrn and thrombin were added at zero time to obtain the final
concenrrations indicated. The lag times were measured at the point where
the concentration of generated thrombin (i. e. total thrombin minus added
thrombin) cxceeded 20 nM
-ao
V" can be considered to be roughly equivalent o the conrribution 2OO
of 3 x 108 activated platelets/ml (2,3, L4).
The addition of factor V" to piatelet rich plasma has a relatively
minor effect on thromboplastin induced thrombin generation. It
increases the peak amount of thrombin observed in the burst by 
=
about 10% and slightly shortens the lag time. Phospholipids, S
however, caused a 2-fold higher thrombin yield when added to z
platelet rich ptasma in the absence of thromboplastin. When E .,
platelet rich plasma was activated by thrombop",,i",'rtiti.""i = 100
phospholipid had, no effect on thrombin generation (Fig.5) and !f
shortened the lag time appreciably. When factor V" and phos- tr
pholipids are added together the effect was not significantly
greater than that of phospholipid alone. These results indicate
that phospholipids are rate limiting to thrombin generation in
normal plasma under our conditions.
Thus it seems that thrombin, in concentrations of less than
5 nM, under the influence of small amounts of thromboplastin
during the lag time provokes a procoagulant reaction in blood
platelets that enables the plasmatic clotting factors to produce a
burst of thrombin formation of 100-200 nM. Of the known
procoagulant functions of the platelets the exposure of procoagu-
lant phospholipids is the most likely to produce this effect.
Fig.5 T}l,e effects of phospholipid and factor Vo on thrombin generation
in platelet rich plasma. Symbols used: (A), 40 pM phospholipid (20%
phosphatidylserinelS0To phosphatidylcholine) and no thromboplastin;
(O), a0 pM phospholipid QA% PSl80% PC) and 1/2.400 diluted thrombo-
plastinl (A), 10 nM factor Vo and no thromboplastin and (*), no addition
Effect of Heparin
When heparin is added to platelet r ich plasma in concentra- E
tions of up to 0.3 U/ml the lag phase is prolonged but. E ZOO
surprisingly, hardly any decrease is seen of the amount of
thrombin eventual ly produced in the burst (Fig.6). In contr ist,
hepann, when added to platelet poor plasma in these concentra-
t ions causes an important inhibit ion (more than 90%) of the
amount of thrombin formed (15). As can be seen from Fig.7 this
dif fcrence between the action of heparin on platelet r ich plasma
and on platelet poor plasma can be explained by the release of
heparin neutral izing material ( in al l  probabil i ty platelet factor 4)
from the tr iggered platelets. Heparin (0.5 Ulml) wi l l  cause only
20% inhibit ion of the peak of thrombin formation in the presence
oi platelet release product(s).
Discussion
The procoagulant effect of blood platelets is known since the
earl iest days of coagulat ion research. I t  was indeed postulated by
Bizzozero in his first description of the blood platelets (16). Many
later observations confirmed the role of platelets in coagulation( r7)|.
We rvanted to investigate what the relat ive importance of
platelet activation is on thrombin generation in a reaction medium
that is as close as possible to native platelet rich plasma.
In platelet rich plasma, recalcification causes a burst of
thrombin formation after a lag time of 8-10 min. This "spontane-
ous" thrombin generation is ini t iated by contact act ivat ion, as i t  is
substantial ly prolonged in factor XII deticient plasma (Fig.3).
The addition of a low amount of thromboplastin (l:2,400) causes
a shortening o[ the lag phase that preceeds a burst of thrombin
formation by 3-5 min, Because this phenomenon was not
observed in platelet poor plasma, it indicates that there is a
combined acrion of thromboplastin and plateles. This effect is
mediated by factor VII because it is not seen in factor VII
deficient plasma (Fig.2). Hirudin, which is a specific inhibitor of
thrombin without known effect on platelets per se is able to
prolong the lag.t ime (Fig.2). Thrombin on the other hand
shortens the taf-time (Fig.3). These observations irldic-ate.that the
effect of thromboplastin on the lag time is mediated by thrombin.
The effect of traces of thrombin in advancing the appearance of a
thrombin burst in whole blood has been reported as early as 1953
o l o rue (rin) 20
Fig.6 The inf luence of  unfract ionated hepar in on thrombin generat ion
in platelet rich plasma. Thrombin generation was started by the addition
of  thromboplast in ( i /2.40{))  in the presence of  (a) .  no hepar int  (b) .  0 I  U/
ml hepar in:  (c) .  0.2 U/ml hepar in and (d) .  0.3 U/ml hepar in
1 0 0
c
Frg. 7 Neutralization of heparin by activated platelet by 5 pM Ca-
ionophore (A223187). (O) Plasma obtained by centrifugation of platelet
rich plasma activated by Ca-ionophore, to which 0.1. unit/ml heparin has
been added. ( ) 0.4 unitlml heparin. (A): control with non activated
platelet poor plasma with addition of 5 pM Ca-ionophore and 0.1 U/ml
heparin
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y Biggs and Macfarlane. The mechanism behind this phenome-
non has remained obscure. however (17). The occurrence of low
concentrations (0.1-1 nM) of thrombin in blood before a
thrombin burst occurs that leads to coagulation has been demon-
strated by Shuman and Majerus (18)
Two products from activated platelets can contribute directly
to thrombin generation: phospholipids and factor V. We added
procoagulant phospholipid or activated factor V in quantities that
are roughly equivalent to the maximal contribution of 3 x 10n
plateletsiml. The effect of factor V" appeared to be minor
compared to that of phospholipids (Fig.5). The combined effect
of phospholipid and factor V, was hardly greater than that of
phospholipid alone; the Iag time was shortened by 30 sec
compared to the curves with phospholipid alone and the peak
activity was not significantly increased. In order not to overload
Fig.5 these data are not shown. We conclude that i t  is probably
the phospholipid produced by the platelets that enhances throm-
bin formation.
Bevers et al. (2) have shown that isolated platelets are capable
of producing procoagulant phospholipids at the outside of their
membrane ("f l ip-f iop"). Under these experimental -condit ions
(106 platelets/ml) thrombin (2 nM) needs the simultaneous
presence of collagen in order to provoke the reaction. Rosing et
al (3) have shown that at higher platelet concentrations thrombin
alone is an efficient trigger. At the platelet concentration we used
(3 x 10d platelets/ml) the requirement for col lagen is abol ished.
Indeed. the addit ion of col lagcn in our svstem. cither with or
u' i thout st irr ing had no effect on thrombin generation in the
presence and in the absence of thromboplastin (results not
ehown.).
We can summarizc our view of the course of events as fol lows.
ln platelet r ich plasma. when coagulat ion is tr iggered bv Cal* and
a low concentrat ion of thromboplastin. thc systcm immediately
after recalcif icat ion can be regarded as platelet poor plasma, in
which inactrve platelets are suspended. Thromboplastin causes
small  amounts of thrombin to be formed. These induce a
procoagulant reaction in thc platelets that starts an explosivc
thrombin formation. From the known procoagulant act ivi t ies of
the platelets- the production of procoagulant phospholipids is the
most l ikely candidate for the explanation of this effect. The factor
V contr ibuted by the platelets seems less important for thrombin
generation than the phosphoiipid is. An additional effect of
thrombin on the activation of factor V und VIl l  during the lag
time cannot be excluded Biggs and Nossel (19) and Josso and
Prou-Wartelle (20) described that at low thromboplastin concen-
trations the factor VII dependent activation of factor IX con-
tr ibutes to thrombin formation, Osterud and Rappaport proved
the existence of this mechanism without reasonable doubt (21).
We could show (experiments to be reported separately) that in
our s)istem. dilutions of thromboplastin of 1:500 and higher cause
an increasingly important contribution of the VII + IX + X
pathway. This means that we cannot exclude the possibility of an
additional contriburion of factor VIII activation to the
phenomena observed. The explosion of thrombin is limited by
exhaustion of the prothrombin available.
The effect of unfractionated heparin on thrombin generation in
plateiet rich plasma is significantlir different from that in platelet
poor plasma. ln platelet rich plasma the main feature of heparin
addition is a prolongation of the lag time of thrombin formation
whereas in platelet poor plasma the decrease of the peak antount
of thrombin is the predominant phenomenon (15).
From Fig.7 it follows that platelets at a physiological concen-
ftarion contain amounts of heparin neutralizing material that are
capable of virtualll' complete neutralization of 0.5 U/ml of
heparin This represents a heparin concentration that in rigor-
ously platelel and PF 4 free plasma wil l  cause more then 957"
28
inhibition of thrombin formation (15). It has been shown that
,mere venip-u-nc-ture, if carried out under routine conditions,
induces platelets to produce a quantity of hepar*l neutraliZing
material equivalent ro 0.183 + 0.067 U/ml of h'eparin (22). T\e
amount of heparin neutralized in our experiments, in which
platelets were maximally triggered with Ca-ionophore, therefore
does not seem to be unrealistically high. We have not identified
the heparin neutralizing material but platelet factor 4 seems to be
the most likely candidate.
Our results demonstrate that heparin in platelet rich plasma
retards thrombin formation but does not diminish the amount of
thrombin eventuallv formed. It therefore seems unlikely that its
antithrombotic effect in vivo is due to inhibition of the bulk of
thrombin formation, especially if the doses given do not result in
plasma levels higher than 0.5 U/ml. From Fig.6 i t  is clear that an
important retardation of thrombin formation can follow from
heparin concentrations as low as 0.10-0.15 U/ml. We postulate
that this retardation is instrumental in obtaining an antithrombo-
tic effect with low doses of heparin- On basis of the data of van
Putten et al. (22) we can assume that a circulating heparin
concentrat ion of 0.1-0.2 U/ml wil l  hardly be detected by routine
laboratory methods. This accounts for the difficulty in finding a
laboratory correlate to the antithrombotic action of low dose
heparin.
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